临床试验/NL-OMON45538

NL-OMON45538已完成不适用

A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics (including food effect), pharmacodynamics and proof of concept of CKD-506 in healthy subjects and inflammatory bowel disease patients - CKD-506 Phase 1 SAD/MAD/FE/POC study

Chong Kun Dang Pharmaceutical Corp.0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Chong Kun Dang Pharmaceutical Corp.
入组人数: 80

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）

入选标准

•healthy male or female volunteers, IBD patients
•18-55 years, inclusive
•BMI: 18.0-32.0 kg/m2, inclusive
•non-smoking

排除标准

•Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating or losing more than 100 milliliters of blood in the 60 days prior the start of this study.

研究者

发起方

Chong Kun Dang Pharmaceutical Corp.

相似试验

CIT013 First in Human study

NL-OMON24009Citryll BV52

A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to investigate the safety, tolerablility, pharmacokinetics (including food and gender effect), and pharmacodynamics of LNP1955 in healthy subjects.Inflammatory disease conditionsrheumatoid arthritis.10003816

NL-OMON42416upin Limited66

A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INS-3001 in healthy subjects and patients with moderate aortic valve stenosis

NL-OMON52051Vifor (International) Inc.30

A first-in-human, randomized, double-blind, placebo-controlled, study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of GLPG4059 in adult, healthy, male subjects.

NL-OMON55090Galapagos NV57

A first-in-human, randomized, double-blind, placebo-controlled study to evaluate, single ascending doses of CIT-013 in healthy volunteers with and without an intravenous lipopolysaccharide challenge and repeat dosing in healthy volunteers and patients with Rheumatoid Arthritis.

NL-OMON56333Citryll84